AGRX - Agile Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures4

Market Cap (intraday) 4.50M
Enterprise Value 1.47M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)0.19
Price/Book (mrq)1.78
Enterprise Value/Revenue 0.11
Enterprise Value/EBITDA -0.09

Trading Information

Stock Price History

Beta (5Y Monthly) 1.07
52-Week Change 3-94.79%
S&P500 52-Week Change 31.77%
52 Week High 3141.0000
52 Week Low 33.3600
50-Day Moving Average 37.6281
200-Day Moving Average 312.5895

Share Statistics

Avg Vol (3 month) 327.53k
Avg Vol (10 day) 343.13k
Shares Outstanding 51.13M
Implied Shares Outstanding 6N/A
Float 8988.41k
% Held by Insiders 10.00%
% Held by Institutions 13.54%
Shares Short (May 14, 2023) 467.93k
Short Ratio (May 14, 2023) 42.5
Short % of Float (May 14, 2023) 46.88%
Short % of Shares Outstanding (May 14, 2023) 46.87%
Shares Short (prior month Apr 13, 2023) 433.81k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 21:50
Last Split Date 3Apr 10, 2023

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 30, 2022
Most Recent Quarter (mrq)Mar 30, 2023


Profit Margin -157.83%
Operating Margin (ttm)-251.77%

Management Effectiveness

Return on Assets (ttm)-94.69%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)12.94M
Revenue Per Share (ttm)20.07
Quarterly Revenue Growth (yoy)116.50%
Gross Profit (ttm)N/A
EBITDA -31.53M
Net Income Avi to Common (ttm)-20.42M
Diluted EPS (ttm)94.0300
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)4.43M
Total Cash Per Share (mrq)4.48
Total Debt (mrq)2.22M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.59
Book Value Per Share (mrq)-10.12

Cash Flow Statement

Operating Cash Flow (ttm)-22.79M
Levered Free Cash Flow (ttm)-9.47M